Denison Mines announces $250 million convertible notes offering
Yale Catriona, the Chief Development Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), recently executed a series of transactions involving the company’s stock. According to a recent filing, Catriona sold shares valued at approximately $447,605. The sales took place on March 17, 2025, with transaction prices ranging from $44.697 to $45.05 per share. The transaction occurred near InvestingPro’s Fair Value estimate for the $3.46 billion market cap company, which has delivered an impressive 67% return over the past year.
In addition to the sales, Catriona also exercised stock options to acquire 10,000 shares at a price of $21.1 per share, amounting to a total of $211,000. Following these transactions, Catriona holds 95,034 shares of Akero Therapeutics directly. The company maintains a strong financial position, with cash reserves exceeding debt obligations and a current ratio of 19.38x.
These transactions were carried out under a pre-established Rule 10b5-1 trading plan, which was adopted on May 24, 2024. For more detailed insights into AKRO’s insider trading patterns and 12 additional exclusive ProTips, visit InvestingPro.
In other recent news, Akero Therapeutics has seen several updates from analysts regarding its price target and stock rating. Citi analysts have raised their price target for Akero Therapeutics to $80, citing promising 96-week SYMMETRY data for efruxifermin (EFX) in patients with compensated cirrhosis caused by metabolic-associated steatohepatitis (MASH F4C). The data showed significant fibrosis improvement, which has been a milestone for this patient group. H.C. Wainwright also increased its price target to $75, highlighting the potential of EFX for treating non-alcoholic steatohepatitis (NASH) with F2/F3 fibrosis. Jefferies adjusted their price target to $75 as well, following positive Phase IIB trial results for Akero’s NASH treatment, particularly in F4 cirrhosis patients. Canaccord Genuity raised their target to $73 after the release of the 96-week SYMMETRY data, expressing confidence in EFX’s efficacy for metabolic disorders. Each firm maintained a Buy rating on the stock, reflecting an optimistic outlook for Akero Therapeutics’ future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.